• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 3. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 4. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

Professional Introduction to 3-(aminomethyl)pentan-3-ylbenzene (CAS No. 127535-26-6)

3-(aminomethyl)pentan-3-ylbenzene, identified by the Chemical Abstracts Service Number (CAS No.) 127535-26-6, is a significant compound in the field of pharmaceutical chemistry and bioorganic synthesis. This molecule, featuring a benzene ring substituted with a pentan-3-yl group and an aminomethyl side chain, has garnered attention due to its unique structural and functional properties. The combination of an amine functionalities with a branched alkyl chain offers versatile reactivity, making it a valuable intermediate in the development of various therapeutic agents.

The structural framework of 3-(aminomethyl)pentan-3-ylbenzene is characterized by its bifunctional nature, which allows for diverse chemical modifications. The presence of the primary amine group (-NH?) provides a nucleophilic site for condensation reactions, while the pentan-3-yl chain introduces steric and electronic influences that can modulate the compound's interactions with biological targets. This dual functionality has been exploited in synthetic chemistry to develop novel derivatives with enhanced pharmacological profiles.

In recent years, there has been growing interest in leveraging such structurally complex molecules for drug discovery. The benzene ring, a common motif in pharmacophores, contributes to the lipophilicity and binding affinity of the compound, while the aminomethyl group facilitates further derivatization. This has led to its incorporation in the synthesis of potential inhibitors and modulators of various biological pathways.

One notable area of research involving 3-(aminomethyl)pentan-3-ylbenzene is its application in the development of kinase inhibitors. Kinases are enzymes that play crucial roles in cell signaling and are frequently targeted in oncology and inflammatory diseases. The compound's ability to mimic natural substrates or interfere with enzyme activity has been explored through structure-based drug design. Recent studies have demonstrated that derivatives of this molecule can exhibit inhibitory effects on specific kinases, suggesting their potential as lead compounds for therapeutic intervention.

The synthesis of 3-(aminomethyl)pentan-3-ylbenzene involves multi-step organic transformations, including alkylation, reduction, and functional group interconversions. Advanced synthetic methodologies have been employed to optimize yield and purity, ensuring that the final product meets pharmaceutical-grade standards. Techniques such as palladium-catalyzed cross-coupling reactions have been particularly useful in constructing the benzene-pentanoyl linkage efficiently.

The pharmacological evaluation of 3-(aminomethyl)pentan-3-ylbenzene and its derivatives has revealed promising activities in preclinical models. For instance, studies have shown that certain analogs can inhibit the proliferation of cancer cells by disrupting key signaling cascades. Additionally, their interaction with receptors or enzymes involved in inflammation has been investigated, highlighting their potential in managing autoimmune disorders.

The role of computational chemistry in designing and optimizing molecules like 3-(aminomethyl)pentan-3-ylbenzene cannot be overstated. Molecular modeling techniques have enabled researchers to predict binding affinities, metabolic stability, and other physicochemical properties before experimental synthesis. This approach not only accelerates the drug discovery process but also reduces costs associated with trial-and-error experimentation.

In conclusion, 3-(aminomethyl)pentan-3-ylbenzene(CAS No. 127535-26-6) represents a compelling scaffold for medicinal chemistry innovation. Its unique structural features and functional versatility make it a valuable building block for developing novel therapeutic agents. As research continues to uncover new applications and synthetic strategies, this compound is poised to play an increasingly important role in addressing unmet medical needs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)